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There is a wide range of important pharmaceuticals used in treatment of cancer. Besides
their known effects on tumor cells, there is growing evidence formodulation of the immune
system. Immunomodulatory drugs (IMiDs®) play an important role in the treatment of
patients with multiple myeloma or myelodysplastic syndrome and have already demon-
strated antitumor, anti-angiogenic, and immunostimulating effects, in particular on natural
killer (NK) cells. Tyrosine kinase inhibitors are directly targeting different kinases and are
known to regulate effector NK cells and expression of NKG2D ligands (NKG2DLs) on tumor
cells. Demethylating agents, histone deacetylases, and proteasome inhibitors interfere
with the epigenetic regulation and protein degradation of malignant cells. There are ﬁrst
hints that these drugs also sensitize tumor cells to chemotherapy, radiation, and NK cell-
mediated cytotoxicity by enhanced expression of TRAIL and NKG2DLs. However, these
pharmaceuticals may also impair NK cell function in a dose- and time-dependent manner.
In summary, this review provides an update on the effects of different novel molecules on
the immune system focusing NK cells.
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INTRODUCTION/BACKGROUND
Immunomodulatory drugs (IMiDs®) have been introduced in the
treatment of cancer with important clinical success. In addition to
classical chemotherapeutic treatments, the novel classes of IMiDs®
have been developed for the treatment of multiple myelo-
ma (MM), myelodysplastic syndrome (MDS), chronic lymphatic
leukemia (CLL), and B cell lymphoma (Bartlett et al., 2004a).
Tyrosine kinase inhibitors (TKIs) are administered in patients
with tumors overexpressing kinases like BCR/ABL, stem cell
factor receptor (c-KIT), platelet-derived growth factor recep-
tor (PDGFR) and vascular endothelial growth factor receptor
(VEGFR). TKIs are used in ﬁrst-line for chronic and acute myeloid
leukemia (CML and AML) with BCR/ABL overexpression as well
as for gastrointestinal stromal tumors (GIST) with c-KIT muta-
tions (Bennasroune et al., 2004). Furthermore, TKIs have been
developed for the treatment of advanced metastatic renal cell
carcinoma (RCC; Pirrotta et al., 2011).
Abbreviations: ADCC, antibody-dependent cell cytotoxicity; AML, acute myeloid
leukemia; CLL, chronic lymphatic leukemia; CML, chronic myeloid leukemia;
CTCL, cutaneous T cell lymphoma; DC, dendritic cell; DLI, donor lymphocyte
infusion; DNAM-1, DNAX accessory molecule-1; GIST, gastrointestinal stromal
tumors; HCC, hepatocellular carcinoma cell; HDAC, histone deacetylase; HDACi,
histone deacetylase inhibitor; IMiD®, immunomodulatory drug; KIR, killer-cell
immunoglobulin-like receptors; MAPK, mitogen-activated protein kinase; MDS,
myelodysplastic syndrome; MIC, MHC class I-related chain molecules; MM, mul-
tiple myeloma; NCR, natural cytotoxicity receptor; NK, natural killer; NKG2DL,
NKG2D ligand; PBMC, peripheral blood mononuclear cells; PDGFR, platelet-
derived growth factor receptor; PI, phosphoinositide; RCC, renal cell carcinoma;
SCID, severe combined immunodeﬁcient; SOCS1, suppressor of cytokine signal-
ing 1; TCL, T cell lymphoma; TKI, tyrosine kinase inhibitor; TSA, trichostatin A;
VEGFR, vascular endothelial growth factor receptor; VPA, sodium valproate.
Demethylating agents such as azacytidine and decitabine
have been approved for treatment of AML, MDS, and other
hematopoietic disorders (Issa et al., 2005; Garcia-Manero, 2008).
Histone deacetylases inhibitors (HDACis) have been designed
as direct antitumor agents with major anti-proliferative effects.
Some HDACis have been approved for the treatment of cutaneous
T cell lymphoma (CTCL) and recently also for peripheral T cell
lymphoma. HDACis are further tested in clinical phase II and III
trials for multiple entities such as cervical, breast, and ovarian
cancer, sarcoma, lymphoma, myeloma, and leukemia (Marks and
Xu, 2009; Khan and La Thangue, 2012; Ning et al., 2012).
In addition, the proteasome inhibitor bortezomib has been
approved for treatment of MM and mantle cell lymphoma
(Voorhees and Orlowski, 2006; Orlowski and Kuhn, 2008).
Current studies addressing the use of immune modulat-
ing pharmaceutics in different other malignant diseases are in
progress. Interestingly, these new pharmaceuticals do not only
show direct antitumor effects, but also impact cellular immunity.
In this review, we sum up the recent knowledge of the inﬂuence
each of these drugs has on natural killer (NK) cells.
Natural killer cells are a heterogeneous lymphocyte population
with cytotoxic antitumor capacity and multiple immunoregula-
tory properties. They express a wide range of activating recep-
tors [e.g. natural cytotoxicity receptors (NCRs), some killer-cell
immunoglobulin-like receptors (KIRs), and NKG2D], as well as
inhibitory receptors (some KIRs, co-receptor NKG2A) that regu-
late NK cell activation and tolerance (Vivier et al., 2011). In the
last years, exiting data revealed that modulation of the balance
between activating and inhibiting NK cell signals, sensitization
of malignant cells to NK cell-mediated cytotoxicity, optimization
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of the cross-talk of NK cells with other immune cells and the
improvement of adoptive NK cell therapeutic protocols may pro-
vide novel immunotherapeutic concepts for treatment of cancer
(Terme et al., 2008).
IMMUNOMODULATORY DRUGS
Thalidomide was described as anti-angiogenic, antitumor, and
immune modulatory agent affecting many cell types. To over-
come the devastating side effects, including congenital defects
when used during pregnancy, novel classes of IMiDs® have been
developed (Bartlett et al., 2004a). The most important IMiDs®
are lenalidomide (CC-5013, Revlimid®) and pomalidomide (CC-
4047,Actimid®) but further thalidomide analogs are under clinical
trials (Bartlett et al., 2004a; Reddy et al., 2008).
Thalidomide and IMiDs® were able to stimulate T cells to pro-
duce IFN-γ and IL-2 leading to NK cell activation (Davies et al.,
2001; Hayashi et al., 2005). In addition, IMiDs® also showed direct
effects on NK cells. Recent preclinical data revealed an augmenta-
tion of NK cell percentages in pomalidomide- and lenalidomide-
treated peripheral bloodmononuclear cells (PBMCs) fromhealthy
donors that was mediated by the phosphoinositide (PI)-3 kinase
signaling pathway causing enhanced IL-2 transcription and secre-
tion in T cells (Hayashi et al., 2005). Pomalidomide induced
expression of CD69 accompanied by a more than twofold increase
of IFN-γ production and enhanced killing of K562 tumor cells
(Payvandi et al., 2005). Interestingly, NK cells were required but
not sufﬁcient for lysis of K562, meaning that cytotoxicity was
also dependent on other cell populations within the PBMCs (Zhu
et al., 2008). In line with that, PBMCs treated with thalidomide,
lenalidomide, or pomalidomide gained an increased killing capac-
ity of MM tumor cells that was lost uponNK cell depletion (Davies
et al., 2001). In addition to enhanced cytotoxicity, lenalidomide,
and pomalidomide also increased antibody-dependent cell cyto-
toxicity (ADCC) toward MM cells (Hayashi et al., 2005). It has
further been conﬁrmed that the effect of pomalidomide on
cytotoxicity and ADCC was induced by IL-2-producing T cells.
Although signaling molecules that could directly mediate NK
cell cytotoxicity and ADCC like ERK or p38 mitogen-activated
protein kinase (MAPK) were not activated by pomalidomide,
both IMiDs® were able to downregulate suppressor of cytokine
signaling 1 (SOCS1) in NK, T, and NKT cells (Gorgun et al.,
2010). Additionally, lenalidomide-treatment resulted in upregu-
lation of CD16, CD40L, and LFA1 on NK cells thereby facilitating
ADCC against MM cells (Tai et al., 2005). Recent work showed
that lenalidomide does not affect NK cell proliferation among
PBMCs but inhibits the production of IFN-γ in IL-12/IL-18
pre-activated, healthy donor-derived, puriﬁed NK cells. Further-
more, the NK cell phenotype was modiﬁed by enhancement
of CD56 and decreased expression of KIRs and NKp46 (Dau-
guet et al., 2010). However, the reduced expression of receptors
involved in NK cell-mediated killing was not sufﬁcient to impair
the cytolytic function of NK cells (Hayashi et al., 2005; Dauguet
et al., 2010).
In vivo, administration of lenalidomide and pomalidomide
resulted in a signiﬁcant increase of NK cells in severe com-
bined immunodeﬁcient (SCID) mice with human lymphoma
xenografts. The combination of IMiDs® together with rituximab
prolonged the median survival and was abrogated by NK cell
depletion (Hernandez-Ilizaliturri et al., 2005). In Raji-bearing
SCID mice, application of IMiDs® led not only to NK cell expan-
sion and activation but also to their migration into tumor beds. In
this model, the effects of IMiDs® seemed to be related to dendritic
cells (DCs) and their secreted cytokines (Reddy et al., 2008).
Remarkably, in patients responding to thalidomide-therapy an
increased percentage of CD56+ cells has been observed (Davies
et al., 2001). This observation is in linewith other studies reporting
an enhanced number of NK cells in patients during IMiD®-
treatment (Bartlett et al., 2004b). In a clinical study addressing
the effects of lenalidomide on MM patients with relapse after
allogeneic stem cell transplantation, the monitoring of immune
cell subpopulations revealed an increase of T, Treg, and activated
NKp44+ NK cells (Lioznov et al., 2010).
To sum it up, IMiDs® mostly positively inﬂuence NK cell
function, either direct or indirect via DC or T cell stimulation.
Nevertheless, effects of IMiDs® on NK cells should be further
investigated in clinical immunomonitoring studies.
TYROSINE KINASE INHIBITORS
Tyrosine kinase receptors are involved in multiple cellular pro-
cesses and have a crucial role in tumor development and progres-
sion. The inhibitors of those receptors are called TKIs and belong
to a broad range of drugs (Bennasroune et al., 2004). Important
TKIs are imatinib (Givec®, Gleevec®) and nilotinib (Tasigna®) that
speciﬁcally inhibit BCR/ABL, PDGFR, and c-KIT, as well as dasa-
tinib (Sprycel®) that additionally targets the SRC kinase (Krusch
andSalih,2011). Furthermulti-target TKIs like sunitinib (Sutent®)
and sorafenib (Nexavar®) have been developed inhibiting various
tyrosine kinases (Pirrotta et al., 2011).
Recent in vitro and in vivo studies indicated both direct
inhibitory effects on immune cells including T and NK cells and
indirect activatory or inhibitory effects on NK cell function via
modiﬁcation of markers on tumor cells caused by TKI-treatment
(Seggewiss et al., 2005; Chen et al., 2008; Schade et al., 2008;Weich-
sel et al., 2008; Fraser et al., 2009). On side of the tumor, a direct
control of the expression of theNKG2D ligands (NKG2DLs)MHC
class I-related chain molecules (MIC)A/B by BCR/ABL has been
shown and was reduced by different TKIs leading to decreased NK
cell-mediated cytotoxicity and IFN-γ production (Boissel et al.,
2006; Salih et al., 2010). A similar effect was shown after imatinib-
treatment of a leukemic cell line transfected with high levels of
BCR/ABL representing an ideal NK cell target. Imatinib led to
diminished killing that was accompanied by decreased ICAM-1
expression on target cells and was most likely due to reduced for-
mation of NK cell/target immunological synapses (Baron et al.,
2002; Cebo et al., 2006). On the NK cell effector side, direct expo-
sure of human NK cells with pharmacological doses of imatinib
hadno impact onNKcytotoxicity or cytokine production,whereas
nilotinib negatively inﬂuenced cytokine production and dasatinib
additionally abrogated cytotoxicity in vitro. The direct modula-
tion of NK cells by dasatinib was apparently based on its impact
on signaling cascades preventing phosphorylation of PI-3 kinase
and ERK1/2 (Salih et al., 2010). Interestingly, inhibition by dasa-
tinib seemed to be reversible as washing NK cells mainly restored
cytotoxicity (Blake et al., 2008; Hassold et al., 2012).
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Further, in a murine model NK cell activation could be induced
by imatinib-treated DC in vitro and in vivo (Borg et al., 2004).
The positive, most likely NK cell-dependent, antitumor effect of
imatinib was further augmented by IL-2 in another murine model
(Taieb et al., 2006). Other data showed, that frequencies of NK cells
were not altered by imatinib-treatment in mice (Balachandran
et al., 2011).
In contrary to the TKIs described so far, treatment of tumor
cells with the multi-kinase inhibitors sorafenib and sunitinib
increased their susceptibility for cytolysis by NK cells. Treatment
of a hepatocellular carcinoma cell (HCC) line with sorafenib did
not affect HLA class I expression but increased membrane-bound
MICA and decreased soluble MICA resulting in enhanced NK
cell-mediated cytotoxicity. Sorafenib led to a decline of the met-
alloprotease ADAM9 that is usually upregulated in human HCC
resulting in MICA shedding (Kohga et al., 2010). Also, incubation
of a nasopharyngeal carcinoma cell line with sunitinib increased
the expression of NKG2DL better than sorafenib leading to a
higher NK cell-mediated cytotoxicity (Huang et al., 2011). On the
other side, in line with the other TKIs mentioned before, phar-
macological concentrations of sorafenib but not sunitinib reduced
cytotoxicity and cytokine production of resting and IL-2-activated
NK cells in vitro by impaired granule mobilization apparently
due to diminished phosphorylation of ERK1/2 and PI-3 kinase.
Notably, sunitinib only altered cytotoxicity and cytokine produc-
tion when added in high doses which were not reached in patients
(Krusch et al., 2009).
In immunomonitoring analysis, NK cell percentages did not
differ between imatinib-treated Philadelphia chromosome posi-
tive ALL patients and healthy donors (Maggio et al., 2011). In
CML patients, the NK cell percentages were decreased at diagnosis
and did not recover during imatinib therapy. This was accompa-
nied by reduced degranulation response to tumor cells (Chen et al.,
2012). Another study compared NK cell numbers of patients who
received imatinibwith completemolecular response formore than
2 years, patients that stopped therapy, and healthy donors. Inter-
estingly, NK cell numbers were signiﬁcantly increased in patients
that stopped therapy. Of note, increasing cell numbers correlated
with increased NK cell activity (Ohyashiki et al., 2012). During
imatinib therapy of GIST patients an increase of INF-γ produc-
tion by NK cells was observed and correlated with a positive
therapy response (Borg et al., 2004). Although GIST patients dis-
played less NKp30+ NK cells and fewer NKp30-dependent lytic
potential, both were at least partially restored during imatinib
therapy. On the other hand, NKG2D showed a normal expres-
sion on NK cells in GIST patients, but nevertheless imatinib
increased NKG2D-dependent cytotoxicity. Additionally, after 2
months of therapy, imatinib led to increased IFN-γ production
of patient-derived NK cells after restimulation with IL-2 or DCs
in vitro (Menard et al., 2009). In contrast to the observation of
NK cell suppression by dasatinib in vitro as well as in murine
models, where dasatinib-treatment led to reduced lysis of tumor
cells, some dasatinib-treated patients showed an increased num-
ber of NK large granular lymphocytes associated with improved
leukemic control and prolonged survival (Fraser et al., 2009; Kim
et al., 2009; Mustjoki et al., 2009; Kreutzman et al., 2010; Tanaka
et al., 2012). Regarding the effects of sunitinib in clinical settings,
there was no signiﬁcant change concerning NK cell numbers mea-
sured in 43 metastatic clear cell renal cancer patients (Powles
et al., 2011). Recently, a link between KIR genotypes and ther-
apy response to TKIs has been assessed. Interestingly, the lower
BCR/ABL1 transcript levels in peripheral blood of 86 ﬁrst-line
dasatinib-treated CML patients after 12 months were associated
with the absence of three inhibitory KIRs and a similar trend was
visible for two activating KIRs including KIR2DS1 (Kreutzman
et al., 2012). KIR genotyping in 174 CML patients on ﬁrst-line
therapy with imatinib showed that the expression of KIR2DS1
was accompanied by a signiﬁcantly lower 2-year probability to
achieve cytogenetic response (Marin et al., 2012). In contrast,
another study showed no signiﬁcant impact of the KIR geno-
type on clinical outcome in 130 CML patients (Ali et al., 2012).
However, missing KIR ligand KIR/HLA genotype combination
might be a prognostic factor as in the case of increased sur-
vival in neuroblastoma patients treated with anti-GD2 antibody
(Tarek et al., 2012).
Altogether, TKIs display various direct and indirect effects on
NK cells and function. Dasatinib, imatinib, and nilotinib showed
a negative inﬂuence on NK cell ligands on tumor cells whereas the
effect of sorafenib and sunitinib revealed an obverse effect. With
exception of imatinib the direct effects on NK cells seem to be
mostly inhibitory and should be further investigated.
DEMETHYLATING AGENTS
DNAhypermethylation followedby silencingof tumor-suppressor
genes is supposed to play an important role in leukemogenesis.
Demethylating agents like azacytidine (5-azacytidine, Vidaza®)
and decitabine (5-aza-2′-deoxycytidine, 5-aza-2′-dc, Dacogen®)
are cytidine analogs irreversibly inhibiting the DNA methyl-
transferase and in addition induce genome-wide damages in
a dose-dependent manner. Demethylating agents have already
revealed their direct effects on malignant cells (Christman, 2002;
Issa et al., 2005; Stone et al., 2009).
It was shown that azacytidine and decitabine alone or com-
bined with other drugs induced expression of the NKG2DLs
MICA/B or UL16-binding proteins (ULBP) on various tumor
cell lines (Rohner et al., 2007; Tang et al., 2008; Wu et al., 2009;
Schmiedel et al., 2011). Interactions of NKG2D with chemically
induced MICB signiﬁcantly enhanced the killing capacity of a NK
cell line upon pre-treatment with decitabine, most likely due to
DNA damage and promotor DNA demethylation (Gasser et al.,
2005; Tang et al., 2008). NK cell-dependent antitumor activity
was also increased upon treatment of patient-derived primary
AML blasts with a combination of demethylating agents and other
differentiation-promoting drugs (Rohner et al., 2007). Demethy-
lating agents do not only affect tumor cells, they additionally
inﬂuence gene expression in effector cells. NK cell lines, clones
and developing NK cells all exhibiting different KIR genotypes,
displayed a stable transcription of KIRs after treatment with
decitabine (Santourlidis et al., 2002; Chan et al., 2005). In contrast
to the augmented tumor susceptibility to lysis upon azanucleoside-
treatment, it has been reported that azacytidine induced expres-
sion of inhibitory KIRs and led to impaired granzyme B
and perforin release resulting in limited cytolytic function
(Gao et al., 2009).
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An important comparative analysis of azacytidine and
decitabine revealed different impacts on NK cell cytotoxicity.
While azacytidine-treated PBMC-derived NK cells displayed a
diminished cytotoxicity, decitabine-treated cells showed the oppo-
site and strongly dose-dependent effect. In line with the impact
on cytotoxicity, azacytidine led to decreased and decitabine to
increased IFN-γ production by NK cells upon stimulation with
tumor cells or IL-2. The expression of activating receptors was
only inﬂuenced by azacytidine resulting in slight downregulation
of CD16, NKG2D, and NKp30 on NK cells. Of note, the rela-
tively short exposure time to demethylating agents in the described
in vitro setting did neither alter the KIR proﬁle of NK cells nor the
NKG2DL expression of target cells that has been described previ-
ously. Altogether, the inhibitory effect of azacytidine seemed to be
caused by impairedmRNA synthesis, whereas decitabine increased
the responsiveness to activation stimuli resulting in enhanced gene
transcription (Schmiedel et al., 2011).
However, one should be aware that these studies have mainly
been performed in vitro and so far analysis of NK cell phenotype
and function from patients treated with demethylating agents are
pending.
HISTONE DEACETYLASES INHIBITORS
Histone deacetylases (HDACs) play an important role in the epige-
netic modulation of gene expression affecting cell-cycle arrest, dif-
ferentiation and apoptosis in all nucleated cells. Mutations in genes
encoding HDACs and alterations in HDAC expression have been
found in many types of cancer. Therefore, inhibition of HDACs
seems to be a good point of attack in tumor therapy (Glozak and
Seto, 2007). Mentionable HDACis are sodium valproate (VPA),
trichostatin A (TSA), sodium butyrate, vorinostat (Zolinza®),
romidepsin (Istodax®), and chidamide (CS055/HBI-8000).
Microarray analysis revealed that VPA augmented MICA/B
expression on HCC cells leading to elevated lysis by NK cells
(Armeanu et al., 2005). A similar effect could be shown in vitro in
treated leukemic blasts fromAML patients that enhanced MICA/B
and ULBP1 expression, thereby increasing cytolysis by KIR–HLA
class I-mismatched cells (Diermayr et al., 2008). Recently, a sim-
ilar effect was shown on a B-ALL cell line and a proportion of
primary B-ALL samples. Those tumor cells upregulated NKG2DL
and displayed an enhanced, NKG2D-dependent degranulation of
NK cells (Jardine et al., 2012). TSA-treated leukemic cell lines
and patient-derived leukemic cells also increased MICA/B expres-
sion via histone acetylation of promotors and mediated NK cell
cytotoxicity (Kato et al., 2007). These NK cell-activating effects
could also be demonstrated for vorinostat and sodium butyrate.
This study further showed a cell-dependent involvement of cyto-
toxicity mediated via DNAX accessory molecule-1 (DNAM-1)
and NCRs (Schmudde et al., 2008). Noteworthy, romidepsin-
dependent upregulation of MICA/B on cancer cells showed an
essential involvement of the glycogen synthase kinase-3, whereas
the sodium butyrate-induced upregulation was inﬂuenced by
increased binding of Sp1 together with heat shock transcrip-
tion factor 1 to the MICA/B promotor (Skov et al., 2005; Zhang
et al., 2009). On the effector side, one of the newest HDACi, chi-
damide, led to enhanced lysis of K562 tumor cells in vitro by
increased expression of proteins involved in NK cell functions like
CD16, NKG2D, and granzyme A. Gene expression studies were
performed and a time-dependent induction of NK cell receptors
(CD16, NKG2D, and KLRG1), cytotoxic enzymes (granzyme and
perforin), and molecules important for apoptosis (FASLG) was
observed (Ning et al., 2012). On the other hand, there is increas-
ing evidence that HDACis can also inhibit cytotoxicity even of
activated NK cells. In one study, VPA- and vorinostat-induced
inhibition was accompanied by diminished expression of NKp46
and NKp30 and reduced granule exocytosis (Ogbomo et al., 2007).
Recent data on the effect of vorinostat on NK cells from healthy
donors and patients with CTCL also demonstrated a suppres-
sion of cytotoxicity in vitro (Anshelevich et al., 2010). A further
study distinguished between activated and resting NK cells and
revealed a downregulation of NKG2D and NKp46 on resting,
VPA-, TSA-, or sodium butyrate-treated, and an additional down-
regulation of NKp44 and CD25 on activated, TSA-treated NK
cells. These HDACis also signiﬁcantly impaired IFN-γ production
of NK cells (Rossi et al., 2012). VPA decreased IFN-γ expression
of cytokine-pre-treated NK cells on mRNA and protein levels that
was associatedbydecreasedphosphorylationof STAT5and attenu-
ated expression of T-bet. Valproic acids further reduced expression
of perforin and granzyme B,whereas only the transcript levels and
not the protein levels of granzyme A and Fas ligand were affected
(Alvarez-Breckenridge et al., 2012).
In a murine tumor model, treatment with TSA showed reduced
expression of NK1.1, NKG2D, and NKp46 accompanied with
diminished IFN-γ production after ex vivo cytokine stimulation
(Rossi et al., 2012). Furthermore, immunomonitoring performed
on romidepsin-treated CTCL patients showed suppression of cel-
lular immune functions, including NK cell cytotoxicity (Kelly-Sell
et al., 2012).
In sum, these data show not only the promising effect on tumor
sensitization to NK cell cytotoxicity, but also a potential nega-
tive impact on antitumor NK cell activity by different HDACis
with exception of new agents like chidamide. However, further
evaluation in clinical studies is needed.
PROTEASOME INHIBITORS
Proteasomes belong to the intracellular machinery responsible for
protein degradation. Inhibitors of proteasomes can directly inhibit
tumor growth or sensitize cells to apoptotic effects of other agents.
The mechanisms by which bortezomib (Velcade®), an impor-
tant proteasome inhibitor, acts, may differ dependent on tumor
targets and still have to be further examined (Voorhees and
Orlowski, 2006).
In general, tumor-treatment with proteasome inhibitors
seemed to sensitize various tumor cells and cell lines such as breast
cancer, melanoma, RCC, CML, and others to NK cell-mediated
lysis (Lundqvist et al., 2006, 2010; Ames et al., 2009; Yong et al.,
2009). First studies showed that bortezomib led to expression
of death receptor DR5 on RCC cells that correlated with sus-
ceptibility toward NK cells (Lundqvist et al., 2006). Further in
vitro analysis indicated that bortezomib-treated tumors hadhigher
TRAIL-induced caspase 8 activity (Lundqvist et al., 2009). Addi-
tionally, bortezomib and other tested proteasome inhibitors with
distinct mechanisms also strongly increased NKG2DL expression
such as ULBP in head and neck squamous cell carcinoma cells and
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Table 1 | Overview on the impact of immunomodulating agents on NK cells.
Drug Indirect effect on NK cells Direct effect on NK cells
IMiDs®
Thalidomide • T cell stimulation leading to increased ADCC and cytotoxicity
of NK cells toward K562 and MM tumor cells (Hayashi et al.,
2005)
• Increased NK cell numbers after therapy in MM patients (Davies
et al., 2001)
• Increased cytotoxicity towardMM tumor cells (Davies et al., 2001)
Lenalidomide • Increased NK cell numbers and activation in Raji-bearing SCID
mice via stimulation of DCs and their cytokines (Reddy et al.,
2008)
• T cell stimulation leading to increased ADCC and cytotoxicity
of NK cells toward K562 and MM tumor cells
(Hayashi et al., 2005)
• No effect on proliferation of NK cells in vitro (Dauguet et al., 2010)
• Increased NK cell numbers in metastatic MM and other advanced
cancer patient (Bartlett et al., 2004b)
• Increased numbers of NKp44+ NK cells in MM patients with
relapse (Lioznov et al., 2010)
• Upregulation of CD56, CD16, CD40L, and LFA1 (Tai et al., 2005;
Dauguet et al., 2010)
• Downregulation of SOCS1, NKAT2, NKB1, CD158ah, and NKp46
(Dauguet et al., 2010; Gorgun et al., 2010)
• Increased cytotoxicity towardMM tumor cells (Davies et al., 2001)
• Inhibition of IFN-γ production in activated NK cells
(Dauguet et al., 2010)
Pomalidomide • Increased NK cell numbers and activation in Raji-bearing SCID
mice via stimulation by DCs and their cytokines (Reddy et al.,
2008)
• T cell stimulation leading to increased ADCC and cytotoxicity
of NK cells toward K562 and MM tumor cells
(Hayashi et al., 2005)
• Upregulation of CD69 (Payvandi et al., 2005)
• Increased IFN-γ production (Payvandi et al., 2005)
• Downregulation of SOCS1 (Gorgun et al., 2010)
• Increased cytotoxicity toward MM and K562 tumor cells
(Davies et al., 2001; Payvandi et al., 2005)
TKIs
Imatinib • Downregulation of NKG2DL on K562 and CML tumor cells
leading to reduced cytotoxicity and IFN-γ production (Salih
et al., 2010)
• Downregulation of ICMA-1 on BCR/ABL-transfected leukemic
tumor cells accompanied by decreased cytotoxicity
(Baron et al., 2002)
• DC stimulation leading to increased NK cell activity in human
and mice (Borg et al., 2004)
• Increased NK cell numbers post therapy (Ohyashiki et al., 2012)
• No impact on cytotoxicity and cytokine production in vitro
(Salih et al., 2010)
• Increased NKp30- and NKG2D-dependent lysis and IFN-γ
production in GIST-patients (Menard et al., 2009)
• Increased INF-γ production in GIST patients correlatedwith clinical
outcome (Borg et al., 2004)
Nilotinib • Downregulation of NKG2DL on K562 and CML tumor cells
leading to reduced cytotoxicity and IFN-γ production (Salih
et al., 2010)
• Inhibition of cytokine production but no effect on cytotoxicity
(Salih et al., 2010)
Dasatinib • Downregulation of NKG2DL on K562 and CML tumor cells
leading to reduced cytotoxicity and IFN-γ production (Salih
et al., 2010)
• Inhibition of cytotoxicity in mice (Fraser et al., 2009)
• Inhibition of cytotoxicity toward K562 and cytokine production
(Salih et al., 2010)
Sorafenib • Increase of MICA on HCC tumor cells and decrease of soluble
MICA leading to enhanced cytotoxicity (Kohga et al., 2010)
• Increased expression of NKG2DL on nasopharyngeal
carcinoma cells leading to enhanced cytotoxicity
(Huang et al., 2011)
• Inhibition of cytotoxicity and cytokine production
(Krusch et al., 2009)
Sunitinib • Increased expression of NKG2DL leading to enhanced
cytotoxicity (Huang et al., 2011)
• Inhibition of cytotoxicity and cytokine production only in
unphysical high doses (Krusch et al., 2009)
(Continued)
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Table 1 | Continued
Drug Indirect effect on NK cells Direct effect on NK cells
Demethylating agents
Azacytidine • Expression of NKG2DL on K562 and Raji tumor cell
(Schmiedel et al., 2011)
• Induction of inhibitory KIRs resulting in decreased cytotoxicity
(Gao et al., 2009)
• Downregulation of CD16, NKG2D, and NKp30
(Schmiedel et al., 2011)
• Inhibition of cytotoxicity toward K562 and Raji tumor cells and
cytokine production (Schmiedel et al., 2011)
Decitabine • Expression of NKG2DL on various tumor cell lines
including K562 and Raji cells leading to enhanced
cytotoxicity (Rohner et al., 2007; Tang et al., 2008;
Wu et al., 2009; Schmiedel et al., 2011)
• General induction of KIRs (Santourlidis et al., 2002)
• Increasing of cytotoxicity toward K562 and Raji tumor cells and
cytokine production (Schmiedel et al., 2011)
HDACis
VPA • Expression NKG2DL on HCC and AML tumor cells leading
to enhanced cytotoxicity (Armeanu et al., 2005;
Diermayr et al., 2008)
• Upregulation of NKG2DL on B-ALL tumor cells leading to
enhanced degranulation (Jardine et al., 2012)
• Downregulation of NKG2D, NKp46, and NKp30 (Ogbomo et al., 2007;
Rossi et al., 2012)
• Inhibition of cytotoxicity toward various tumor cells
(Ogbomo et al., 2007; Alvarez-Breckenridge et al., 2012)
• Inhibition of cytokine production (Alvarez-Breckenridge et al., 2012;
Rossi et al., 2012)
TSA • Increased NKG2DL expression on various leukemic tumor
cells leading to enhanced cytotoxicity (Kato et al., 2007)
• Downregulation of NKG2D and NKp46 on resting and additionally
NKp44 and CD25 on activated NK cells (Rossi et al., 2012)
• Downregulation of NK1.1, NKG2D, and NKp46 in mice
(Rossi et al., 2012)
• Inhibition of cytokine production in human and mice (Rossi et al., 2012)
Vorinostat • Sensitizing various tumor cells toward cytotoxicity
(Schmudde et al., 2008)
• Downregulation of NKp46 and NKp30 (Ogbomo et al., 2007)
• Inhibition of cytotoxicity toward various tumor cells
(Ogbomo et al., 2007; Anshelevich et al., 2010)
• Inhibition of cytokine production (Rossi et al., 2012)
Sodium
butyrate
• Sensitizing various tumor cells toward cytotoxicity
(Schmudde et al., 2008)
• Downregulation of NKG2D and NKp46 on resting NK cells
(Rossi et al., 2012)
• Inhibition of cytokine production (Rossi et al., 2012)
Romidepsin • Upregulation of NKGDL on tumor cells (Skov et al., 2005) • Inhibition of cytotoxicity toward K562 tumor cells (Kelly-Sell et al., 2012)
Chidamide • Upregulation of CD16, NKG2D, granzyme, perforin, KLRG1, and
FASLG (Ning et al., 2012).
• Increased cytotoxicity toward K562 tumor cells (Ning et al., 2012)
Proteasome inhibitors
Bortezomib • Induction of DR5 on renal cell carcinoma leading to
enhanced susceptibility (Lundqvist et al., 2006)
• Upregulation of NKG2DL on diverse cell lines and head and
neck squamous cell carcinoma cells leading to enhanced
susceptibility (Vales-Gomez et al., 2008; Butler et al., 2009)
• Increased caspase 8 activity leading to enhanced susceptibility
toward murine and human tumors (Lundqvist et al., 2009)
• Downregulation of HLA class 1 on human MM and MHC class I
on murine leukemic tumor cells (Hallett et al., 2008; Shi et al., 2008)
• Upregulation of DNAM-1 and NKG2DL in primary plasma cells
and NKG2DL on B-ALL tumor cells leading to increased
degranulation of NK cells (Soriani et al., 2009; Jardine et al., 2012)
• Pro-apoptotic effect on resting NK cells (Wang et al., 2009)
• Downregulation of NKp46 resulting in diminished activity
(Wang et al., 2009)
• Inhibition of cytotoxicity of activated NK cells toward MM tumor cells
(Feng et al., 2010)
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other cell lines (Vales-Gomez et al., 2008; Butler et al., 2009). This
could be recently conﬁrmed as bortezomib augmented NKG2DL
on a B-ALL cell line and a proportion of primary B-ALL samples.
All treated cells displayed an enhanced degranulation of NK cells
mediated by NKG2D signaling (Jardine et al., 2012). In line with
that in vitro treated primary plasma cells upregulated DNAM-1
and NKG2DL accompanied with increased degranulation of NK
cells (Soriani et al., 2009). On the contrary, other studies described
a bortezomib-dependent downregulation of HLA class I on MM
cell lines and patient-derived MM cells in a dose- and time-
dependent manner. This effect was also observed on MM cells
derived from patients treated with bortezomib (Shi et al., 2008).
However, besides this augmentation of cytotoxicity, pro-apoptotic
effects of bortezomib on PBMC-derived, resting NK cells have
been reported. This effect might be due to oxidative stress as
glutathione signiﬁcantly abolished total NK cell apoptosis by pre-
venting loss of mitochondrial membrane potential. Furthermore,
bortezomib-treated NK cells downregulated NKp46 leading to
diminished NKp46-mediated NK cell activity (Wang et al., 2009).
Besides, NK cytotoxicity could also be diminished by downregu-
lation of TRAIL via inhibition of NFκB on IL-2-activated NK cells
upon bortezomib-treatment in vitro (Feng et al., 2010).
Murine studies showed a NK cell-sensitizing effect of
bortezomib-treated renal tumors to both perforin/granzyme and
TRAIL-mediated lysis in vitro. In addition, bortezomib-treatment
combined with Treg depletion signiﬁcantly enhanced tumor
lytic capacity of adoptively transferred autologous NK cells in
vivo (Lundqvist et al., 2009). Of note, additional work in this
mouse model revealed that bortezomib-treated tumors underly-
ing enhanced NK cell killing paradoxically developed resistance
to antigen-speciﬁc T cells that was probably due to changes in
proteasomal processing and presentation of antigens (Lundqvist
et al., 2010). In another in vitro mouse model, sensitization of
tumor cells with bortezomib led to lysis that was mediated by
enhanced DR5 and Fas expression accompanied with downregu-
lation of MHC class I. The authors could show in a murine tumor
model that bortezomib-treatment in bone marrow transplanta-
tion together with NK cell immunotherapy increased survival
(Hallett et al., 2008).
Natural killer cells from RCC patients showed an increased
killing against autologous tumor cell lines after ex vivo sensi-
tization with bortezomib (Lundqvist et al., 2006). A ﬁrst phase
I trial showed safety in adoptive transfer of activated NK cells.
This protocol was combined with Treg depletion and bortezomib-
treatment for tumor sensitization prior to adoptive NK cell
transfer into patients with advanced stage of cancer (Lundqvist
et al., 2011).
Although tumor cells displayed an increased NK cell suscepti-
bility upon stimulation with proteasome inhibitors, the effect on
NK cells seemed to be contrary and should be closer examined.
In addition, further clinical phase II and III studies are needed to
address the speciﬁc tumor entity and combination therapy that
might promise best efﬁcacy of the combination of tumor sensiti-
zationwith proteasome inhibitors and donor lymphocyte infusion
of NK cells (NK-DLI).
CONCLUDING REMARKS AND OUTLOOK
In summary, the heterogeneous impact on NK cell function
reported for the different immunemodulating substances, referred
in this review, is mediated by either indirect or direct effects on
NK and tumor cells and is further depending on the tumor entity,
timing, and dosing of the different pharmaceutics (Table 1).
The majority of IMiDs® predominantly mediates immune
stimulation positively inﬂuencing NK cell-mediated antitumor
capacity. TKIs,HDACis, andproteasome inhibitors exhibit various
effects. They display mostly negative impacts on NK cell function
although treatment of tumor cells may result in contradictory
results by sensitization to apoptosis-induction. Exceptions were
the new HDACi chidamide and the TKI imatinib that showed a
positive effect on NK cell activation. Both of the demethylating
agents described exhibit opposite effects on NK cell function.
For better understanding of the underlying mechanisms,
unambiguous data on NK cell function from preclinical and clin-
ical studies are still needed. In addition to the complex balance
of both tumor and NK cells, there are multiple effects on the
other players of the immune system such as antigen presenting
cells and cytolytic T cells that regulate the outcoming immune
effects.
Finally, an ideal therapeutic concept for cancer patients might
combine inhibitors of immunosuppression with tumor sensitizers
and cellular therapy protocols such as adoptive NK cell transfer.
This review underlines the urgent need of further immunomon-
itoring studies that should address functional aspects of immune
cells on autologous patient-derived tumor cells under therapywith
immune modulating agents. Growing knowledge from such stud-
ies will allow the right choice of the ideal immune modulators at
the optimal dosing and timing to obtain the best possible outcome
for the patients.
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